1. Stocks
    2. /
  2. Island Pharmaceuticals Ltd (ASX: ILA)
    3. /

Island Pharmaceuticals Ltd (ASX: ILA) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Island Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $90.31 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 296.10 million
Earnings per share -0.036
Dividend per share N/A
Year To Date Return -32.56%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Island Pharmaceuticals Ltd (ASX: ILA)
    Latest News

    No posts found.

    ILA ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Island Pharmaceuticals Ltd

    Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Its Isla101, a drug being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The company was founded by David Foster on May 25, 2020 and is headquartered in Camberwell, Australia.

    ILA Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    02 Nov 2026 $0.27 $-0.02 -6.90% 268,089 $0.30 $0.30 $0.26
    30 Oct 2026 $0.29 $-0.04 -12.31% 666,262 $0.33 $0.33 $0.29
    29 Oct 2026 $0.33 $0.00 0.00% 64,707 $0.33 $0.33 $0.32
    28 Oct 2026 $0.33 $0.02 6.45% 34,205 $0.32 $0.33 $0.32
    27 Oct 2026 $0.31 $0.00 0.00% 38,586 $0.32 $0.32 $0.31
    26 Oct 2026 $0.31 $-0.02 -6.15% 213,419 $0.33 $0.33 $0.31
    23 Oct 2026 $0.33 $0.01 3.13% 108,817 $0.32 $0.33 $0.31
    22 Oct 2026 $0.32 $-0.02 -5.88% 495,437 $0.34 $0.34 $0.30
    21 Oct 2026 $0.34 $0.01 3.03% 58,444 $0.35 $0.35 $0.34
    20 Oct 2026 $0.33 $-0.01 -2.99% 29,929 $0.35 $0.35 $0.33
    19 Oct 2026 $0.34 $-0.01 -2.90% 71,000 $0.34 $0.35 $0.34
    16 Oct 2026 $0.35 $0.00 0.00% 103,217 $0.35 $0.35 $0.34
    15 Oct 2026 $0.34 $-0.04 -10.53% 647,267 $0.38 $0.38 $0.34
    14 Oct 2026 $0.38 $0.00 0.00% 582,648 $0.37 $0.39 $0.37
    13 Oct 2026 $0.38 $0.01 2.70% 161,779 $0.37 $0.38 $0.37
    12 Oct 2026 $0.37 $0.01 2.74% 15,958 $0.37 $0.37 $0.37
    09 Oct 2026 $0.37 $-0.01 -2.70% 274,247 $0.37 $0.38 $0.37
    08 Oct 2026 $0.37 $0.01 2.74% 203,657 $0.37 $0.37 $0.36
    07 Oct 2026 $0.37 $0.00 0.00% 440,062 $0.38 $0.38 $0.37
    06 Oct 2026 $0.37 $-0.02 -5.26% 79,955 $0.39 $0.39 $0.37

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    03 Dec 2025 Christopher Ntoumenopoulos Buy 844,568 $59,119
    Exercise of options.
    03 Dec 2025 Jason Carroll Buy 974,930 $68,245
    Exercise of options.
    03 Dec 2025 Christopher Ntoumenopoulos Exercise 844,568 $59,119
    Exercise of options.
    03 Dec 2025 Jason Carroll Exercise 974,930 $68,245
    Exercise of options.
    02 Dec 2025 Jason Carroll Transfer 366,666 $199,832
    As advised by the company. Transfer executed with third party for participation in previous capital raise
    12 Nov 2025 Christopher Ntoumenopoulos Issued 2,750,000 $275
    Issue of options.
    12 Nov 2025 David Foster Issued 2,000,000 $200
    Issue of options.
    12 Nov 2025 Jason Carroll Issued 5,000,000 $500
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Christopher Ntoumenopoulos Non-Executive Director Sep 2024
    Mr Ntoumenopoulos is a company director and corporate advisor with more than 20 years of experience in capital markets, corporate finance, and strategic growth. He has expertise in capital raising, corporate advisory, and guiding public and private companies through key stages of growth.
    Dr David Foster Chief Executive OfficerManaging DirectorExecutive Director Oct 2020
    Dr Foster is a biotechnology entrepreneur and public company executive with more than 25 years of experience founding, building and leading life sciences organizations. Throughout his career, he has helped launch multiple biotechnology companies, technologies from early-stage concepts through clinical development and corporate growth. Dr Foster is also a co-founder of BioNTX, a life sciences industry association supporting the growth of the biotechnology ecosystem in North Texas and has served on the boards of numerous biotechnology companies.
    Mr Jason Alan Carroll Non-Executive ChairmanNon-Executive Director Jul 2025
    Mr Carroll has experience in life sciences executive, with a 34-year career in the industry. Jason has managed roles of responsibility in operations (Pharmaceutical Production Management), sales & marketing (Specialist Medical Representative, Product Management, Sales & Marketing Management & Business Unit Director) and business development (Early Product Development Lead, Associate Director of Market Access, Associate Director of Asia Regional Business Development and Business Licensing & Acquisition).
    Mr Cameron Jones Chief Financial OfficerCompany Secretary Dec 2023
    -
    Cameron Jones Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr William James Garner 40,440,073 13.67%
    BNP Paribas Nominees Pty Ltd <IB AU Noms RetailClient> 38,058,749 12.86%
    Mr Jason Alan Carroll 32,074,930 10.84%
    Dr Daniel Tillett 20,973,789 7.09%
    Dr Jack Yetiv 7,000,000 2.37%
    Mr Neville James Miles 6,442,487 2.17%
    Mr David Foster 6,306,829 2.13%
    Buprestid Pty Ltd <Hanlon Family S/F A/C> 3,553,285 1.20%
    Citicorp Nominees Pty Limited 3,341,231 1.13%
    S3 Consortium Pty Ltd 2,250,054 0.76%
    Mr Alistair Robert Baker 2,160,869 0.73%
    Mr Terence Leo Tobin & Mrs Elizabeth Joy Tobin 2,000,000 0.68%
    Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C> 1,924,340 0.65%
    Mr Phillip Richard Perry-i 1,810,000 0.61%
    Non Correlated Capital Pty Ltd <Investius Pb Micro Cap A/C> 1,660,000 0.56%
    Bayesian Holdings Pty Ltd <M&I A/C> 1,650,000 0.56%
    Lillucy Pty Ltd <Lilypily Super Fund A/C> 1,650,000 0.56%
    Mr Anthony Stephen Cormack 1,645,000 0.56%
    Mr Phillip Richard Perry-ii 1,635,714 0.55%
    Mr Ross Earl Henry 1,600,000 0.54%
    Mrs Patricia Fernandes Dias De Almeida 1,453,146 0.49%

    Profile

    since

    Note